SWOT Analysis: BRISTOL MYERS SQUIBB Bristol Myers Sqibb SWOT:Weaknesses and an analysis of their accounting policies

Bristol-Myers Squibb was formed after the merger between Bristol Myers and Squibb Pharmaceuticals. The merger took place in 1989, this merger created the second largest drug company in the world. The company headquarters are in New York City and has a workforce of over 35,000 employees. Since the merger, Bristol-Myers Squibb has endeavored to be the leading developer, marketer and licenser of pharmaceutical healthcare products that are used for treatment of cancer, HIV / AIDS, cardiovascular diseases, hepatitis, and rheumatoid arthritis.

The company has been facing some challenges especially in regards to loss of market share for their biggest selling drugs to the generic drug companies. This mostly happens when the market exclusivity period of the drugs they have invented expires. This forces the company...

The company has been aggressively working towards acquiring the smaller pharmaceutical companies especially the ones that are in the late stages of their clinical drug tests, these would boost the company's sales as well as boosting its commercial potential.
Weaknesses of Bristol-Myers Squibb

Bristol-Myers Squibb's main weakness is the exposure to generic drugs after the expiry of their drug patents. Many companies that deal with generic drugs always come up with cheaper drugs that serve the same purpose as the drugs developed by the major pharmaceutical companies. This makes the company's sales to drop drastically as people always go for the generic and cheaper drugs. The generic drugs are as good as the other drugs, and they are highly recommended by hospitals due to their cheapness.

Due…